hit counter
Avenue Therapeutics, Inc. (ATXI) Stock News Sentiment & Price - Sentifly
ATXI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Avenue Therapeutics, Inc. (ATXI)

USA
Drug Manufacturers - Other
NASDAQ
ATXI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATXI Latest news
GlobeNewsWire
Neutral
Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
2021-11-09 21:30

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $2.6 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The offering equates to 1,946,787 shares at a price to the public of $1.34 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

GlobeNewsWire
Neutral
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
2021-10-25 07:00

Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meeting Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meeting

Benzinga
Neutral
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday
2021-06-14 10:54

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID-19 Results: After a protracted delay, Gaithersburg, Maryland-based Novavax reported preliminary results showing its coronavirus candidate NVX-CoV2371 met the primary endpoint of the Phase 3 PREVENT trial in the U.S. and Mexico.

GlobeNewsWire
Neutral
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
2021-06-14 07:00

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its New Drug Application (“NDA”) seeking approval for IV tramadol.

Newsfile Corp
Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
2021-04-21 22:34

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avenue and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...

PRNewsWire
Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
2021-04-19 22:09

NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI).  Such investors are advised to contact Robert S.

Zacks Investment Research
Negative
Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?
2021-04-19 07:06

Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon

PRNewsWire
Neutral
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
2021-04-13 23:30

NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI).  Such investors are advised to contact Robert S.

Pulse2
Negative
ATXI Stock: Over 15% Decrease Pre-Market Explanation
2021-04-13 08:18

The stock price of Avenue Therapeutics, Inc. (Nasdaq: ATXI) fell by over 15% pre-market. This is why it happened.

GlobeNewsWire
Neutral
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
2021-04-13 06:30

The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA

Loading more news...